Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. Co. discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. Co.'s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. The RVPH stock yearly return is shown above.
The yearly return on the RVPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2024 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RVPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|